Acorda loses its last shot at protecting its cash cow franchise drug. It’s up to Inbrija now

Acorda has lost its last-ditch attempt to retain control of the cash cow it badly needed to sustain the company. The Supreme Court has refused to hear its argument against a lower court ruling that opened the gate to knockoffs of its multiple sclerosis drug Ampyra.